Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment

BACKGROUND: Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects. METHOD: An open-label, randomized pilot study compared changes in fasting lipids and HIV-1 RNA in 104 HIV-infected adults with PI-associated hyperlipidemia (fasting...

Descripción completa

Detalles Bibliográficos
Autores principales: Keiser, Philip H, Sension, Michael G, DeJesus, Edwin, Rodriguez, Allan, Olliffe, Jeffrey F, Williams, Vanessa C, Wakeford, John H, Snidow, Jerry W, Shachoy-Clark, Anne D, Fleming, Julie W, Pakes, Gary E, Hernandez, Jaime E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548524/
https://www.ncbi.nlm.nih.gov/pubmed/15647105
http://dx.doi.org/10.1186/1471-2334-5-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548524/
https://www.ncbi.nlm.nih.gov/pubmed/15647105
http://dx.doi.org/10.1186/1471-2334-5-2

Ejemplares similares